ANAPTYSBIO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ANAPTYSBIO, INC. (ANAB) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $50.16 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2020-08-10
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$5.70M.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$7.74M.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was -$11.71M, a 125.73% decline year-over-year.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was $45.52M.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $57.42M, a 77.19% increase from fiscal 2018.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was $32.41M, a 8.18% increase from fiscal 2017.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $29.96M.
- ANAPTYSBIO, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2016 was -$452.00K, a 101.53% decline from fiscal 2015.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2020-06-30 | $50.16M 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | -$5.70M 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $57.42M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $69.30M 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $32.96M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$7.74M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $32.41M 10-K · filed 2020-03-02 | |||
| 2018-09-30 | $212.22M 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | -$24.13M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | -$11.71M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $29.96M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | -$24.56M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | -$20.48M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | $45.52M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$452.00K 10-K · filed 2019-02-28 | |||
| 2016-09-30 | -$4.55M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | -$1.10M 10-Q · filed 2017-08-10 | |||
| 2015-12-31 | $29.47M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |